Joykem ODT 300 Tablet contains Amisulpride 300 mg as its active ingredient, an atypical antipsychotic primarily indicated for the treatment of schizophrenia and other psychotic disorders. Amisulpride exerts its therapeutic effect by selectively blocking dopamine D2 and D3 receptors in the brain, thereby modulating dopaminergic neurotransmission associated with psychotic symptoms such as hallucinations, delusions, and thought disorders. The orally disintegrating tablet (ODT) formulation facilitates rapid disintegration and absorption in the oral cavity, enhancing patient compliance, especially in those with swallowing difficulties. Joykem ODT 300 is typically prescribed for both acute and maintenance phases of schizophrenia, aiming to reduce psychotic episodes and prevent relapse. It may also be utilized off-label for other psychiatric conditions as deemed appropriate by a healthcare professional. Common adverse effects include extrapyramidal symptoms, hyperprolactinemia, sedation, and gastrointestinal disturbances, necessitating regular monitoring during therapy. Caution is advised in patients with a history of cardiac disorders, seizures, or renal impairment. Dosage adjustments should be individualized based on clinical response and tolerability. Joykem ODT 300 should be administered under strict medical supervision, with adherence to prescribed dosing schedules to optimize therapeutic outcomes and minimize potential risks.